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Abstract
Introduction. Implantation of cardioverter-defi brillator (ICD) is an acknowledged strategy in primary prevention of sudden 
cardiac death (SCD). The aim of this study was to assess the number and adequacy of ICD interventions and occurrence 
of modifi cations of device parameters and pharmacotherapy changes, in patients with dilated cardiomyopathy receiving 
primary SCD prevention.
Material and methods. Retrospective analysis included 138 consecutive patients (123 males, 15 females) with is-
chaemic (IDCM) and non-ischaemic dilated cardiomyopathy (NIDCM), who underwent ICD implantation. The analysis 
comprised the number of ventricular tachyarrhythmia episodes, the number and appropriateness of ICD interventions, 
occurrence of ICD reprogramming and pharmacotherapy changes.
Results. ICD interventions occurred in 28% of subjects, pharmacotherapy changes in 27,5% and device parameters 
modifi cations in 55,8%. Patient’s age and absence of atrial fi brillation appeared to be signifi cant factors decreasing 
the risk of ICD interventions. AF presence was connected with high percentage of inadequate interventions. Ventricular 
arrhythmias presence and device parameters changes appeared to be more frequent in patients with NIDCM than with 
IDCM. NIDCM appeared to be an independent risk factor for ICD reprogramming.
Conclusions. ICD interventions are relatively rare in patients receiving primary SCD prevention. Patient’s age and absen-
ce of atrial fi brillation appeared to be signifi cant factors decreasing the risk of ICD interventions. Ventricular arrhythmias 
presence and device parameters changes appeared to be more frequent in patients with NIDCM than with IDCM.
Key words: cardioverter-defi brillator, dilated cardiomyopathy
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Introduction
Patients with implantable cardioverter-defi brillator (ICD) 
indications for primary prevention of sudden cardiac death 
(SCD) are a huge group of patients with an implanted devi-
ce. Since the publication of the Guidelines for management 
of patients with ventricular arrhythmias and the prevention 
of sudden cardiac death in 2006, their number is constantly 
growing. Interrogation of these devices, which should be 
done every 3–6 months [1] is a major burden for the health 
care system. During a routine follow-up visit (FUV), medical 
history since patient’s last visit is taken, a physical exami-
nation is performed and the ICD’s memory is read (interro-
gation), which shows i.a. interventions of the device due to 
recognition of life threatening ventricular tachyarrhythmias 
(AI, adequate interventions). According to various sources, 
the percentage of patients with an implanted device of the 
indications for primary prevention of sudden cardiac death, 
with ischaemic (IDCM) or non-ischaemic dilated cardiomy-
opathy (NIDCM), who experience a discharge from the ICD, 
varies between 20–35.5% [2–6], whereas 14.5–22.5% 
of which are inadequate (IAI, inadequate interventions) 
[4–7], that is, when the device mistakenly recognize the 
rhythm as requiring intervention — usually as a result of 
supraventricular tachyarrhythmias with rapid ventricular 
response [3]. Further activities performed during a FUV 
is checking of the other parameters of the device (battery 
status, bradycardia stimulation parameters — sensing and 
pacing, tachyarrhythmia detection and therapy settings), 
and then a decision is made whether to leave the previo-
us settings or reprogram them. Sometimes during the 
FUV modifi cation of pharmacotherapy (MOP) is done, but 
patients with ICDs are also under constant control of the 
clinical cardiologist, so MOP are rather rare during routine 
FUV. Using the recommended by the producers algorithms 
for discrimination between ventricular and supraventricu-
lar arrhythmias, optimal bradycardia pacing settings and 
optimal detection and therapy for ventricular arrhythmia 
settings reduces mistakes commited by the device and 
minimizes the need for changes.
When there are no episodes of ventricular arrhythmia 
recorded in the memory of ICD, none of the parameters of 
the device is changed and pharmacotherapy is regarded 
as optimal, the FUV boils down to simple interrogation of 
ICD with the conclusion that everything is in order, what is 
a burden for both patients (absence at work, a long journey 
to the department, sometimes the need for an accompany-
ing person) and for outpatient department that from year to 
year must take care of a growing crowd of patients [8]. That 
is the reason, why remote monitoring of ICDs seems to be 
more and more interesting. The aim of the present study 
was to evaluate the number and adequacy of interventions, 
frequency of reprogramming of ICDs and MOP in patients 




We conducted a retrospective study, which included 
consecutive patients (n = 138, 15 females, 123 males, 
mean age 65 ± 12 [range 23–87] years) hospitalized in 
the Department of Electrocardiology in order to implant 
an ICD in 2010–2011 due to IDCM or NIDCM defi ned as 
reduced left ventricular ejection fraction (LVEF) that is 35% 
or less and heart failure in New York Heart Association 
(NYHA) class II or greater. Additional criteria were: optimal 
pharmacotherapy for heart failure, expected survival time 
of at least one year, state at least 40 days after myocar-
dial infarction. Exclusion criteria were: hospitalization for 
replacement or up-grade of the system, the defi brillator 
with cardiac resynchronization therapy function (CRT-D), 
patient primarily planned for implantation of a CRT-D sy-
stem, cardiac surgery other than coronary artery bypass 
graft, dual system (pacemaker at the contralateral side), 
history of cardiac arrest, the presence of congenital heart 
defects or genetically determined arrhythmias, loss of 
contact with the clinic. Of the 520 patients initially enrolled 
in the study, only 138 (26.54%) met the inclusion criteria. 
All participants were informed about the aim of the study 
and provided written consent of participation. The study 
protocol was approved by a local ethics committee (Komisja 
Bioetyczna, Okręgowa Izba Lekarska, Kraków).
Methods
Medical history from hospitalization and records from the 
in-offi ce FUV were analysed. On admission, following va-
riables were collected: age, gender, date of implantation, 
cause of cardiomyopathy (IDCM or NIDCM), LVEF, NYHA 
class and presence or history of atrial fi brillation (AF). All 
in-offi ce FUV were registered. We analysed data printed 
from the programmer, plots of detected arrhythmias and 
comments written by the physician. We recorded dates of 
visits, number of interventions, type of intervention (anti-
-tachycardia pacing [ATP] or cardioversion [CV]), adequacy 
of intervention (AI and INAI), number of recorded ventricular 
fibrillations (VF), ventricular tachycardias (VT), nonsu-
stained ventricular tachycardias (nsVT), supraventricular 
tachycardias (SVT), MOP (if any) and modifi cation of device 
parameters (ROD, reprogramming of ICD device) defi ned 
as: changes in bradycardia pacing, changes in threshold 
or sensing settings, changes in detection of VT/VF, 
changes in therapy of VT/VF, changes in programming 
algorithms recommended by producer. VT zone was defi ned 
as 167–200 beats per minute (bpm), and VF zone was 
defi ned as 200 bpm or more. Additionally, fast ventricular 
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tachycardia zone (FVT) defi ned as ventricular tachycardia 
within the range of 200–240 bpm was activated in some 
cases, in order to treat slow episodes of VF by ATP fi rst. 
nsVTs were ventricular tachyarrhythmias monitored and 
recorded by a device, but too short to be classifi ed as VT 
(arrhythmias which did not dropped in detection zone) and 
provoke the intervention of ICD. SVTs were tachyarrhyth-
mias classifi ed by an ICD as supraventricular with the use 
of various discrimination algorithms.
Statistical analysis
Descriptive parameters of quantitative variables included 
arithmetic mean ± standard deviation (SD), median, maxi-
mum and minimum value, and sample size (n). Differences 
in quantitative variables between groups were tested using 
the Student t test for independent samples or the Mann-
-Whitney test, depending on the variable distribution.
Descriptive parameters of qualitative variables inclu-
ded numbers and percentages and were presented in the 
contingency tables. Differences in qualitative variables 
between groups were tested using the 2 test or the exact 
Fisher test. Kaplan-Meier survival curves were used to 
evaluate survival free from ICD intervention or modifi cation 
of pharmacotherapy.
Dichotomy of variables: NYHA and LVEF were based 
on the mean and median across the base. The variables 
signifi cantly affecting survival to the intervention or mo-
difi cation were included stepwise into a multivariate Cox 
proportional hazard model. The verifi cation of the statistical 
signifi cance of the regression coeffi cients was performed 
by the Wald test. Statistical hypotheses were verifi ed at α 
= 0.05. Calculations were performed using the STATISTICA 
10.0 PL package (StatSoft, Inc.).
Results
During the observation period from the ICD implantation 
to the last documented visit in the clinic (mean value 
616 days), interventions of the device occurred among 28% 
of patients. MOP was performed in 27.5% patients and ROD 
was implemented in 55.8% of subjects. Among patients 
who had ICD interventions during this time, 59% were 
treated by CV, and 74.4% by ATP. Specifi cation of the other 
analysed qualitative and quantitative variables is contained 
in the Table 1 and 2. There were no statistically signifi cant 
differences observed in terms of analysed variables (age, 
gender, NYHA class, LVEF, IDCM, AF) between separated 
groups of subjects — with and without: interventions, MOP 
and ROD respectively.
Kaplan-Meier curves for the probability of survival 
free from the fi rst intervention, fi rst MOP and fi rst ROD are 
shown in Figure 1. Survival free form above-mentioned 
Table 1. Description of quantitative variables





NYHA class (1, 2, 3, 4) 138 2 1 2 2 4
LVEF (%) 138 25 6 25 10 35
Time to 1st intervention 39 319 226 272 41 881
Time to 1st modifi cation of pharmacotherapy 38 340 272 275 39 951
Time to 1st modifi cation of parameters 77 353 297 251 19 1147
Total VF (from check-ups) 27 5 10 1 1 38
Total FVT (from check-ups) 6 3 4 1 1 11
Total VT (from check-ups) 27 4 5 2 1 21
Total nsVT (from check-ups) 66 1128 6743 12 1 54 539
Total SVT (from check-ups) 22 330 1293 9 1 6102
Total interventions from check-ups 39 1 1 1 1 3
Total adequate interventions from check-ups 34 1 1 1 1 3
Total CVs from check-ups 23 1 0 1 1 2
Total ATP from check-ups 29 1 0 1 1 2
Total modifi cation of pharmacotherapy from 
check-ups
38 1 0 1 1 2
Total modifi cation of parameters from check-ups 77 2 1 1 1 5
NYHA — New York Heart Association; LVEF — left ventricle ejection fraction; VF — ventricular fi brillation; FVT — fast ventricular tachycardia; VT — ventricular tachycardia; nsVT — non-sustained ventricular tachy-
cardia; SVT — supraventricular tachycardia; CV — cardioversion; ATP — antitachycardia pacing
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Table 2. Study group characteristics — description of qualitative 
variables
Variable n %
Occurrence of intervention No 99 71.7
Yes 39 28.3
Modifi cation of pharmacotherapy No 100 72.5
Yes 38 27.5
Modifi cation of parameters No 61 44.2
Yes 77 55.8
VF No 111 80.4
Yes 27 19.6
FVT No 132 95.7
Yes 6 4.3
VT No 111 80.4
Yes 27 19.6
nsVT No 72 52.2
Yes 66 47.8
SVT No 116 84.1
Yes 22 15.9
CV No 115 83.3
Yes 23 16.7
ATP No 109 79.0
Yes 29 21.0
Total 138 100.0
VF — ventricle fi brillation; FVT — fast ventricle tachycardia; VT — ventricular tachycardia; nsVT — 
non-sustained ventricular tachycardia; SVT — supraventricular tachycardia; CV — cardioversion; 
ATP — antitachycardia pacing
Table 3. Multivariate analysis of the prognostic factors for intervention of ICD, modifi cation of pharmacotherapy and modifi cation of para-
meters of ICD respectively, using the Cox regression model
Parameter HR 95% CI p value
Intervention Age 0.972 0.948–0.997 0.027
Atrial fi brillation (absence) 0.528 0.277–1.004 0.05
Modifi cation of pharmacotherapy LVEF (%) 0.948 0.897–1.002 0.061
Atrial fi brillation (absence) 0.572 0.302–1.084 0.087
Modifi cation of parameters Non-ischaemic 
dilated cardiomyopathy
1.776 1.063–2.966 0.028
HR — hazard ratio; CI — confi dence interval; LVEF — left ventricular ejection fraction
events was on average 550 ± 341 days [26–1301], 549 
± 344 days [26–1308], and 473 ± 372 days [19–1372] 
respectively.
The multivariate analysis performed using Cox regres-
sion model is presented in Table 3. It was revealed that the 
significant factors in reducing the risk of ICD intervention 
are: age (HR = 0.972, 95% CI: 0.948–0.997, p = 0.027) 
and an absence of AF (HR = 0.528, 95% CI: 0.277–1.004, 
Figure 1. Kaplan-Meier curves for the probability of survival free 
from cardioverter-defi brillator (ICD) intervention (A), modifi cation of 
pharmacotherapy (B) and reprogramming of ICDs (C)
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Table 4. Characteristics of patients with NIDCM and IDCM, occurrence of particular types of ventricular arrhythmias and types of intervention
Characteristics NIDCM IDCM Total p value
n % n % n %
Gender Male 27 93.1 96 88.1 123 89.1 0.348
Female 2 6.9 13 11.9 15 10.9
Age < 64 years 22 75.9 40 36.7 62 44.9 < 0.001
≥ 64 years 7 24.1 69 63.3 76 55.1
NYHA II 16 55.2 80 73.4 96 69.6 0.058
III + IV 13 44.8 29 26.6 42 30.4
LVEF < 25% 9 31.0 31 28.4 40 29.0 0.748
≥ 25% 20 69.0 78 71.6 98 71.0
AF No 11 37.9 77 70.6 88 63.8 0.001
Yes 18 62.1 32 29.4 50 36.2
VF No 21 72.4 90 82.6 111 80.4 0.220
Yes 8 27.6 19 17.4 27 19.6
FVT No 29 100.0 103 94.5 132 95.7 0.236
Yes 0 0.0 6 5.5 6 4.3
VT No 25 86.2 86 78.9 111 80.4 0.378
Yes 4 13.8 23 21.1 27 19.6
nsVT No 12 41.4 60 55.0 72 52.2 0.190
Yes 17 58.6 49 45.0 66 47.8
CV No 21 72.4 94 86.2 115 83.3 0.076
Yes 8 27.6 15 13.8 23 16.7
ATP No 21 72.4 88 80.7 109 79.0 0.328
Yes 8 27.6 21 19.3 29 21.0
CV + ATP No 26 89.7 104 95.4 130 94.2 0.221
NIDCM — non-ischaemic dilated cardiomyopathy; IDCM ischaemic dilated cardiomyopathy; NYHA — New York Heart Association; LVEF — left ventricular ejection fraction; AF — atrial fi brillation; FVT — fast 
ventricle tachycardia; VF — ventricle fi brillation; VT — ventricular tachycardia; nsVT — non-sustained ventricular tachycardia; CV — cardioversion; ATP — antitachycardia pacing
p = 0.05). Presence of NIDCM is a significant risk factor for 
the ROD (HR = 1.776, 95% CI: 1.063–2.966, p = 0.028). 
There were no predictors among analysed variables 
for MOP.
Among patients suffering from NIDCM, there was noti-
ced a higher percentage of persons with AI and INAI, and 
lower of those remaining without any intervention (60% vs 
23.3% vs 18.2% respectively). Interestingly, in this group 
of subjects the percentage of ROD was greater than in the 
group of patients suffering from IDCM (35.5% vs 14.8%, 
p < 0.057). Ventricular tachyarrhythmia occurrence was 
also more common in patients with NIDCM than with IDCM 
(25.9% vs 13.2%, p = 0.075). Among the subjects with AF, 
the percentage of patients with INAI was higher than of 
those without any interventions (67.7% vs 20%, p = 0.048). 
Main characteristics of patients with IDCM and NIDCM, 
particular types of ventricular arrhythmias and types of 
intervention are presented in Table 4.
Among patients suffering from ventricular arrhyth-
mias, compared with those free of them, frequency of 
ICD interventions was signifi cantly higher (43.5% vs 3.8%, 
p < 0.001), especially considering adequate ones (40% vs 
0%, p < 0.001). Also the percentage of patients with MOP 
was higher (37.6% vs 11.3%, p < 0.001), than among group 
of patients without ventricular arrhythmias. Comparing 
groups of patients in terms of the presence of interventions, 
ROD was more frequent in group with interventions than 
without (17.6% vs 3.8%, p = 0.052).
A proportion of patients with ROD due to intervention 
in response to ventricular tachyarrhythmia was 31.4%, 
whereas when intervention was inadequate, this percen-
tage was 3.8% (signifi cant difference, p = 0.004). ROD 
was performed among all subjects with NIDCM, AF, NYHA 
class > 2 and LVEF < 25%. Among the other part of stu-
died population, a proportion of ROD was 53,1% (100% 
vs 53.1%, p = 0.008).
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In our study survival free from intervention, MOP and 
ROD was relatively long, contrary to literature, in which 
RODs were significantly less frequent, after 6 months 
after implant [18].
INAIs are a major problem among patients with ICDs 
and affect mainly patients with AF [3]. Experiencing repe-
titious interventions and fear of them, diminish the quality 
of life, may also lead to anxiety and depressive disorders 
[19, 20]. In our study, the lack of AF signifi cantly reduced 
the risk of intervention. We conclude that despite the use of 
advanced algorithms of discrimination of supraventricular 
and ventricular arrhythmias, still too many patients suffer 
from inappropriate detection of supraventricular arrhythmia 
as VT or VF, and INAI as a consequence.
Managing patients with heart failure includes allevia-
tion of signs and symptoms, prevention from hospitalization 
and improving survival [21]. Eligibility for ICD implantation 
occurs only in patients whose pharmacological treatment 
is optimal. During the post implantation period, beside 
regular ICD check-ups, all the patients are under control 
of clinical cardiologists and general practitioners, therefore 
the percentage of MOP in our study is relatively low (27%). 
During FUV, MOP, which is directly related to arrhythmia and 
is made to minimize the risk of inappropriate intervention 
or the occurrence of VT/VF, is necessary. Other MOPs made 
by a specialist during FUV, associated with other symptoms 
or comorbidities, could also be made by a general pra-
ctitioner. In our study population, we have not found any 
factors predisposing to MOP among analysed features. In 
contrast, there were signifi cantly more MOP in the group 
of patients with ventricular arrhythmia, in comparison to 
the group without.
The percentage of RODs in the observed group was 
55.8%. According to literature, up to 78% interrogations 
of the ICD does not involve taking any action [22]. Con-
sidering that the number of patients with implantable 
devices is increasing, there are attempts being made 
to include these patients in remote monitoring systems 
(RM). The most debatable issue concerning RM is safety 
issue, especially in the case of ICDs and CRT-D. Guédon-
-Moreau et al. [23] in the ECOST trial confirmed the safety 
and effectiveness of RM of patients with ICDs. Moreover, 
patients controlled by RM had significantly lower inciden-
ce of NI and INAI and up to 72% less hospitalizations. 
In our study the percentage of RODs is relatively high. 
Probably it results from both the fact that to the RODs 
we also included changing the parameters of stimula-
tion, but also because the stimulation pulse amplitude 
was adjusted to the threshold value during the FUV, not 
automatically. In all patients in the group with NIDCM, 
AF, NYHA > 2, and LVEF < 25% device parameters were 
modified, which indicates that these patients should 
 Discussion
Primary prevention of SCD means i.a. supplying patients 
at high risk of cardiac arrest due to VT/VF with ICDs. On 
the basis of both the MADIT-II and SDC-HeFT studies, as 
well as DEFINITE study, there have been distinguished 
a group of people, which benefits most from ICD implan-
tation for primary prevention of SCD, that is patients with 
IDCM and NIDCM [9–11]. Currently, the largest group 
of patients eligible for ICD implantation for primary pre-
vention of SCD is patients with IDCM [10]. It was found 
that a low LVEF is the most important independent risk 
factor for SCD in patients after myocardial infarction (MI) 
[12]. Although it has been shown that patients with EF 
< 35% benefit from ICD implantation [10], it is known 
that the low fraction is neither sufficiently sensitive nor 
specific tool for estimating the risk of SCD [13]. Similarly, 
in our study, we observed no influence of LVEF on the 
occurrence of intervention and ventricular arrhythmias. 
For years, the SCD risk stratification factors have been 
searched in the above mentioned group of patients, 
but so far none of these methods obtained the rank of 
guidelines. Currently it is believed that the key issue is 
to look for arrhythmia substrate. In patients after MI the 
re-entry loop around the infarction scar is responsible for 
the formation and maintenance of life-threatening ven-
tricular arrhythmias [14]. The mechanism of SCD in pa-
tients with NIDCM is less clear [15]. In our study, a higher 
percentage of patients with AI and INAI was observed in 
patients with NIDCM in comparison to IDCM. Similarly, 
the percentage of ROD as well as ventricular arrhythmias 
was higher in this group of patients. We found that the 
occurrence of NIDCM is an independent risk factor for 
ROD. Unfortunately, so far no good enough stratification 
factors of mortality in patients with NIDCM have been 
found. Our study suggests that among patients with an 
ICD, it is the patients with NIDCM that deserve special 
attention. This finding is particularly interesting because 
it was previously believed that patients with NIDCM are 
younger, possess fewer comorbidities and thus a lower 
mortality risk supporting their candidacy for ICD to 
reduce SCD.
In our study the percentage of patients suffering from 
interventions (28%) is comparable to that reported in 
large trials. A major percentage of interventions was ATP 
(74.4%) comparing to CV (59%). ATP seems to be espe-
cially beneficial, due to reduction of painful discharges, 
which considerably worsens quality of life among ICD re-
cipients in primary prevention [16]. What is interesting, in 
our study age reduced the risk of intervention. It may be 
explained by higher risk of death due to non-arrhythmic 
causes, but it has not been proven in literature [17]. 
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be taken under special care. ROD for obvious reasons 
was also more frequent in patients with interventions. 
In our study, NIDCM was the independent risk factor for 
modification of parameters ICD.
Limitations
Limitations of this study include its retrospective nature 
and small study sample, which may have prevented us 
from detecting statistical signifi cance between analysed 
qualitative and quantitative variables. Small study sample 
is a result of strict inclusion criteria which let us exclude 
the majority of initially enrolled patients.
Conclusion
Patient’s age and absence of atrial fi brillation appeared 
to be signifi cant factors decreasing the risk of ICD in-
terventions. Ventricular arrhythmias presence and device 
parameters changes appeared to be more frequent in 
patients with non-ischaemic than with ischaemic dilated 
cardiomyopathy.
Confl icts of interests
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Streszczenie
Wstęp. Implantacja kardiowerterów-defi brylatorów (ICD) jest uznaną strategią leczniczą w prewencji pierwotnej nagłego 
zgonu sercowego (SCD). Celem pracy była ocena liczby i adekwatności interwencji ICD oraz modyfi kacji parametrów 
urządzenia i farmakoterapii u pacjentów z kardiomiopatią rozstrzeniową (DCM) w prewencji pierwotnej SCD.
Materiał i metody. Retrospektywnie przebadano 138 pacjentów z ICD (123 mężczyzn, 15 kobiet) wszczepionym z powo-
du niedokrwiennej (IDCM) i nieniedokrwiennej (NIDCM) DCM. Przeanalizowano liczbę epizodów tachyarytmii komorowej, 
liczbę i adekwatność interwencji ICD oraz modyfi kacji parametrów urządzenia i farmakoterapii.
Wyniki. U 28% pacjentów zarejestrowano interwencje ICD, u 27,5% modyfi kowano farmakoterapię, u 55,8% zaś zmie-
niano parametry urządzenia. Wiek chorych oraz brak napadów migotania przedsionków (AF) były istotnymi czynnikami 
zmniejszającymi liczbę interwencji. Obecność napadów AF była związana z istotnym pojawianiem się nieadekwatnych 
interwencji. Tachyarytmie komorowe i związaną z tym modyfi kację parametrów urządzenia istotnie częściej zanotowano 
u osób z NIDCM niż z IDCM. Nieniedokrwienna DCM jest niezależnym istotnym czynnikiem determinującym liczbę mo-
dyfi kacji parametrów urządzenia.
Wnioski. Interwencje ICD serca rzadko się zdarzają w prewencji pierwotnej SCD. Wiek pacjentów oraz brak napadów 
AF są istotnymi czynnikami zmniejszającymi liczbę interwencji ICD. Tachyarytmie komorowe i modyfi kacje parametrów 
urządzenia są szczególnie częste u pacjentów z NIDCM w porównaniu z osobami z IDCM.
Słowa kluczowe: kardiowerter-defi brylator, kardiomiopatia rozstrzeniowa
(Folia Cardiologica 2015; 10, 2: 71–78)
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Komentarz. Opieka nad chorymi z wszczepionym kardiowerterem-defi brylatorem 
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W pracy oryginalnej Joanny Pudło i wsp. przedstawiono jednoośrodkowe wyniki obserwacji średnioterminowej w grupie 
chorych z profi laktycznie wszczepionym kardiowerterem-defi brylatorem (ICD) w wyniku istotnego uszkodzenia lewej 
komory o różnej etiologii, czyli w subpopulacji obecnie najczęściej leczonej tą metodą [1].
Odsetek chorych z interwencjami ICD, sięgający 28% — zwłaszcza w średnim okresie obserwacji nieprzekraczającym 
2 lat — jest odsetkiem istotnym i wynikiem porównywalnym z podawanym w dostępnych doniesieniach. W badaniu SCD-
-HeFT, które najlepiej przystaje do komentowanej pracy, interwencje wystąpiły u 31% chorych podczas 5 lat obserwacji, 
czyli rocznie średnio u 7,5% [2]. Natomiast w badaniach obserwacyjnych częstotliwość interwencji w podobnych popu-
lacjach ocenia się na 20–30% w czasie 1–2 lat, a w populacji niewyselekcjonowanej — nawet na ponad 40% [3, 4]. 
Okres kilkunastu miesięcy po wszczepieniu ICD jest związany z najwyższym zagrożeniem interwencjami [3] i podobny 
trend widać na rycinie 1 w komentowanym artykule. W obserwacjach średnioterminowych chorych z ICD wszczepionym 
profi laktycznie prawdopodobieństwo pierwszej interwencji określano na 11–15% dla interwencji adekwatnych i około 
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Liczba chorych z adekwatnymi interwencjami ICD zależy nie tylko od obecności tachyarytmii komorowych ale i od 
sposobu programowania [7, 8]. Różne strategie ustalania stref detekcji i sekwencji terapii mogą mieć wpływ nie tylko 
na możliwość eliminacji bolesnych wyładowań ICD, ale nawet na rokowanie długoterminowe [9]. W populacji z choro-
bą wieńcową i ICD wszczepionym w ramach profi laktyki pierwotnej stwierdziliśmy ostatnio skuteczność przynajmniej 
jednej terapii niskonapięciowej (ATP) u 85% pacjentów [4]. Dominujące wykorzystanie ATP w badanej grupie — u 75% 
chorych z interwencjami ICD jako zjawisko samodzielne lub w skojarzeniu z terapią wysokoenergetyczną — pośrednio 
potwierdza zastosowanie optymalnych strategii doboru programowania urządzeń przez Autorów, choć brak dokład-
nych danych na ten temat pozostawia pewien niedosyt. W tym miejscu w pracy brakuje też wyraźnego rozgraniczenia 
analizy na interwencje adekwatne i nieadekwatne. Interwencje nieadekwatne mogą wystąpić u aż 1/4 chorych z ICD, 
co jest szczególnie obciążające dla pacjentów bez terapii adekwatnych [3, 10]. Migotanie przedsionków (AF) to jeden 
z najistotniejszych czynników ryzyka nieadekwatnych interwencji ICD i sytuacja taka znalazła swoje odzwierciedlenie 
w wynikach prezentowanej pracy [9]. Autorzy nie podają, czy część spośród zanotowanych w badanej grupie nieade-
kwatnych interwencji była spowodowana uszkodzeniem elektrody. Wynika to zapewne ze zbyt krótkiego okresu obser-
wacji; problem ten może narastać w dalszych latach. W starszych doniesieniach uszkodzenie elektrody występowało aż 
u 25% chorych z ICD w 10-letniej obserwacji, a nieadekwatna interwencja urządzenia jest często pierwszym objawem 
dysfunkcji elektrody. Nowsze typy urządzeń zawierają algorytmy różnicujące szumy uszkodzeń i pozwalają na redukcję 
nieadekwatnych interwencji z tego powodu, co nie zmienia faktu, że problem uszkodzenia elektrod jest jedną z waż-
niejszych „ciemnych stron” terapii za pomocą ICD.
Trudny do skomentowania jest fakt, że istotnie częściej zmieniano farmakoterapię u chorych z arytmiami komorowymi 
i interwencjami urządzenia. Niestety nic nie wiadomo o tych zmianach; czy dotyczyły one strategii up-stream, czy le-
czenia o potencjalnym efekcie antyarytmicznym? Natomiast próba rozwiązania problemu poprzez zmiany w programie 
urządzenia u tylko 3,8% chorych z nieadekwatnymi interwencjami jest zaskakująco niska. Co prawda samo wystąpie-
nie AF nie korelowało z częstszymi wskazaniami do modyfi kacji terapii farmakologicznej, ale — być może — w wymie-
nionej wyżej podgrupie było to postępowanie z wyboru, jeśli założy się, że większości przypadków za nieadekwatne 
interwencje odpowiadało AF. Temu z kolei wydaje się intuicyjnie przeczyć fakt, że zmiany w programie dotyczyły wszyst-
kich chorych z AF, pozawieńcową etiologią niewydolności serca w klasie NYHA wyższej niż II i frakcją wyrzutową poniżej 
25%, czyli potencjalnie „idealnych kandydatów” do nieadekwatnych interwencji ICD. Z tych wątpliwości wynika moje 
skojarzenie z równaniem z wieloma zmiennymi zawarte w tytule komentarza. W celu uporządkowania rozważań warto 
podkreślić wzrastające zastosowanie ablacji przeznaczyniowej, zwłaszcza w przypadku problemów związanych z napa-
dami AF, jako metody wspierającej efekty opieki nad chorymi z ICD lub poddawanych terapii resynchronizującej [11].
Praca jednoośrodkowa zawsze pozostaje pod wpływem schematów postępowania i zasad przyjętych w tymże ośrod-
ku. Dlatego przedstawione w artykule Joanny Pudło i wsp. krzywe przeżycia bez punktów końcowych, takich jakich 
jak interwencja w zakresie farmakoterapii czy reprogramowania, odzwierciedlają też częstotliwość rutynowych lub 
ponadplanowych wizyt pacjentów. Nie znamy dokładnych powodów ani schematów decyzji związanych z punktami 
końcowymi — mogą wynikać z indywidualnych przekonań lekarza kontrolującego. Moim zdaniem komentarza wymaga 
nieco arbitralne stwierdzenie, że w przypadku braku interwencji czy braku arytmii zazwyczaj nie przeprogramowuje 
się urządzenia. To zazwyczaj prawda, ale chciałbym zwrócić uwagę na konieczność weryfi kacji aktywnego programu 
urządzenia. Mimo że programowanie urządzeń wciąż nie jest przedmiotem jednoznacznych rekomendacji, to uprzednio 
wprowadzony program może znacznie odbiegać od aktualnej wiedzy medycznej lub nawet zawierać groźne dla życia 
chorego błędy.
Każda praca — niezależnie od swoich ograniczeń — dotycząca problematyki obserwacji odległej chorych z ICD, zwłasz-
cza pochodząca z dużego ośrodka z tradycjami, rozszerza naszą wiedzę lub budzi twórcze wątpliwości. Na podstawie 
wyników przedstawionych przez Autorów widać wyraźnie, że wszczepialne urządzenia zapewne długo jeszcze nie będą 
autonomicznym bytem typu implant and forget, a nieunikniony rozwój telemedycyny, technologii urządzeń i algoryt-
mów programowania nie zastąpią trudnych decyzji klinicznych podejmowanych ostatecznie przez zespół opiekujący 
się pacjentami.
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